Alpha-1-Proteinase Inhibitor (Human)
Classification: Alpha-1-proteinase inhibitor
Action/Kinetics: Alpha-1-PI is the enzyme that is deficient in alpha-1-antitrypsin disease. This disease causes a progressive breakdown of elastin tissues in the alveoli, resulting in emphysema. Often fatal, alpha-1-antitrypsin disease is usually manifested in the third and fourth decades of life. Prolastin is a sterile, lyophilized product obtained from pooled human plasma that is nonreactive for the HIV antibody and the hepatitis B surface antigen. t 1/2: 4.5 days. Therapeutic serum levels: Approximately 80 mg/dL, although such levels may not reflect actual functional alpha-1-PI levels.
Uses: Panacinar emphysema due to congenital alpha-1-proteinase deficiency.
Contraindications: Clients with PiMZ or PiMS phenotypes of alpha-1-antitrypsin deficiency.
Special Concerns: Use with caution in clients at risk for circulatory overload. Safety and efficacy for use in children not determined.
Side Effects: Although precautions are taken during the manufacture of this product, it is possible that hepatitis and other infectious viruses may be present. Miscellaneous: Delayed fever up to 12 hr following treatment, dizziness, lightheadedness, mild transient leukocytosis.
How Supplied: Powder for injection: 20 mg/mL after reconstitution